November 13, 2026

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Senior Executive Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Notice of Investment in Boston Medical Sciences, Inc. by CVC Fund "TOHO Ventures"

TOHO HOLDINGS CO.,LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter "TOHO HOLDINGS") is pleased to announce that it has invested in Boston Medical Sciences, Inc. (Headquarters: Tokyo; Representative Director: Masaki Okamoto; hereinafter "BMS") through the CVC Fund "TOHO Ventures".

1. Purpose of investment

BMS is a company engaged in the development and clinical deployment of an AI system that supports laxative-free CT colonography.. Colorectal cancer is one of the most common diseases worldwide in terms of both incidence and mortality, and there is a strong need to improve patient outcomes through early detection and early treatment. However, current colonoscopy requires patients to take laxatives beforehand, which places a burden on them and is considered one of the factors hindering improvement in screening rates. To address this challenge, BMS is developing the "Laxative-Free Virtual Colonoscopy® Examination System."

The system combines a virtual bowel-cleansing AI, which eliminates residual matter from CT scan images, with an AI that assists clinicians in detecting polyps. It has been designated for priority review of Software as a Medical Device (SaMD) by the Ministry of Health, Labour and Welfare (MHLW), and has completed its clinical trial in Japan. In addition, as a stepping stone toward global expansion, the system was granted Breakthrough Device designation by the FDA in May 2026, and was selected for the FDA's Total Product Life Cycle Advisory Program (TAP) in June 2026, which enables early and ongoing engagement with the FDA and other stakeholders*. BMS conducts collaborative research with the 3D Imaging Research group at Harvard Medical School and Massachusetts General Hospital (MGH), and is also advancing joint research and partnerships with medical institutions in Japan.

TOHO HOLDINGS decided to invest in BMS in recognition of its proprietary AI technology development capabilities toward the realization of laxative-free CT colonography, its strategic approach to addressing the unmet medical need of reducing the burden of colorectal cancer screening, and the steady progress in its development and regulatory initiatives both in Japan and globally. Through this investment, TOHO HOLDINGS aims to create business synergies and co-create value by leveraging the Group's pharmaceutical distribution network.

*The product is an investigational device under development and has not been approved or cleared in Japan or the U.S. It is not available for sale or distribution. Breakthrough Device Designation does not constitute marketing authorization.

2. Overview of Boston Medical Sciences

Company name	Boston Medical Sciences, Inc.
Location	Chuo-ku, Tokyo, Japan
Representative	Masaki Okamoto
Established	April 2023
Business content	Development and clinical deployment of a non-invasive AI-powered colorectal cancer screening system
URL	https://b-ms.tech/en/

3. Overview of the fund

Fund Name	TOHO Ventures (TOHO-GB Global Life Science Fund, L.P.)
Total AUM	10 billion yen
Fund Term	10 years
Investment Focus	Drug Discovery, Medical Devices, etc.
General Partner	Global Brain Corporation
Limited Partner	TOHO HOLDINGS CO.,LTD.

4. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS, we believe that it will contribute to increasing the Group's corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.